Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

27
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
08/22/2014 08/25/2014 08/26/2014 08/27/2014 08/28/2014 Date
70.63(c) 71(c) 71.24(c) 70.7(c) 69.4(c) Last
64 830 63 155 72 422 80 903 72 373 Volume
-0.04% +0.52% +0.34% -0.76% -1.84% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications. It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec. The Partnered Discovery segment involves technologies for the generation of... 
Sector
Biotechnology & Medical Research
Calendar
09/09 | 03:30pmPresentation
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 62,1 M
EBIT 2014 -14,9 M
Net income 2014 -13,4 M
Finance 2014 263 M
Yield 2014 -
Sales 2015 68,1 M
EBIT 2015 -2,64 M
Net income 2015 -8,73 M
Finance 2015 247 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 25,3x
EV / Sales 2015 23,3x
Capitalization 1 830 M
More Financials
Latest news on MORPHOSYS AG
2d ago EMERGENT BIOSOLUTIONS : and MorphoSys Sign License Agreement to Co-Develop and C..
08/20 MORPHOSYS : and Emergent BioSolutions Sign License Agreement to Co-Develop and C..
08/20 MORPHOSYS : to Host Conference Call on License Agreement with Emergent to Co-Dev..
08/19 EMERGENT BIOSOLUTIONS : MorphoSys and Emergent BioSolutions Sign License Agreeme..
08/06 MORPHOSYS : Patent Application Titled "Use of c-Fms Antagonists" Published Onlin..
07/28 MorphoSys AG Reports Results for the First Six Months of 2014
07/28 CELGENE : MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
07/23 GALAPAGOS : MorphoSys and Galapagos Advance Joint Antibody Program in Inflammato..
07/21 MORPHOSYS : to Host Q2 2014 Conference Call on 28 July 2014
07/21 MORPHOSYS : Receives Additional Patents on Novel Antibody Platform Ylanthia in t..
07/18 MORPHOSYS : Receives Additional Patents on Novel Antibody Platform Ylanthia in t..
06/12 MORPHOSYS : and Merck Serono Enter Strategic Immuno-Oncology Collaboration
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
MorphoSys AG : Income Statement Evolution
More Financials
EPS Revisions
MorphoSys AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF